OMCL Stock Chart & Stats
$702.01
$0.00(0.00%)
At close: 4:00 PM EDT
$702.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$630.00 - $961.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$31.41B
Enterprise Value$1.43B
Total Cash (Recent Filing)$314.86M
Total Debt (Recent Filing)$189.67M
Price to Earnings (P/E)37.6
Beta-0.08
Next Earnings
Feb 11, 2027EPS Estimate
7.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.97
Shares Outstanding45,614,883
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-12.17
Price to Book (P/B)1.69
Price to Sales (P/S)1.76
P/FCF Ratio23.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,063.70Price Target Upside51.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)42.84
Revenue Forecast (FY)$23.36B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationStrong operating and free cash flow indicates that recent earnings are supported by real cash generation, giving Omnicell greater flexibility to fund product development, customer deployments, and debt reduction while improving resilience through the next several quarters.
Lower LeverageSubstantially lower leverage strengthens the balance sheet and reduces financial risk, leaving more capacity to absorb uneven hospital spending, invest in cloud and automation offerings, and pursue customer growth without relying as heavily on external financing.
Platform And Pipeline ExpansionA growing and maturing pipeline, combined with customer interest in Titan XT and OmniSphere, supports a broader platform opportunity beyond hardware replacement. Integrated workflow, visibility, and workforce tools could deepen the installed base and recurring revenue over time.
Bears Say
Weak And Volatile Revenue TrendThe sharp TTM revenue decline and historically uneven top-line performance indicate that demand conversion remains inconsistent. This can limit operating leverage, complicate planning, and make sustained profitability improvement dependent on a more reliable refresh and implementation cycle.
Delayed Bookings ConversionBack-end-weighted bookings and lengthy conversion periods defer revenue recognition and make near-term results sensitive to customer contracting and implementation schedules. The delay can create quarter-to-quarter variability even when pipeline activity and long-term demand remain constructive.
Persistent Component Cost PressureOngoing memory and related component cost inflation can pressure gross margins and offset gains from cost efficiency or favorable product mix. If sustained, the headwind may reduce the profitability contribution from hardware deployments while pricing and customer adoption adjust.
Omnicell News
OMCL FAQ
What was Omnicell’s price range in the past 12 months?
Omnicell lowest stock price was $630.00 and its highest was $961.50 in the past 12 months.
What is Omnicell’s market cap?
Omnicell’s market cap is $31.41B.
When is Omnicell’s upcoming earnings report date?
Omnicell’s upcoming earnings report date is Feb 11, 2027 which is in 103 days.
How were Omnicell’s earnings last quarter?
Omnicell released its earnings results on Oct 29, 2026. The company reported $10.896 earnings per share for the quarter, beating the consensus estimate of $7.853 by $3.043.
Is Omnicell overvalued?
According to Wall Street analysts Omnicell’s price is currently Undervalued.
Does Omnicell pay dividends?
Omnicell does not currently pay dividends.
What is Omnicell’s EPS estimate?
Omnicell’s EPS estimate is 7.72.
How many shares outstanding does Omnicell have?
Omnicell has 45,614,883 shares outstanding.
What happened to Omnicell’s price movement after its last earnings report?
Omnicell reported an EPS of $10.896 in its last earnings report, beating expectations of $7.853. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Omnicell?
Currently, no hedge funds are holding shares in MX:OMCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omnicell Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,063.70 (51.52% Upside)
$1,063.70 (51.52% Upside)
Blogger Sentiment
Neutral
MX:OMCL Sentiment 50%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.14%
12-Months-Change
Fundamentals
Return on Equity
3.50%
Trailing 12-Months
Asset Growth
5.55%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Omnicell
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
OMCL Company Deck
OMCL Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive. The company exceeded third-quarter revenue and EBITDA guidance, raised full-year EBITDA and EPS guidance, reported growing and increasingly mature pipeline activity, and highlighted customer validation for Titan XT and OmniSphere. The main challenges were timing variability in back-end-weighted bookings, modest near-term top-line growth, lower fourth-quarter revenue guidance, memory-cost pressure, a modest 340B-related ARR impact, and the multi-year timeline for OmniSphere monetization. The positive operating results, strategic progress, and pipeline commentary significantly outweighed the stated challenges.View all MX:OMCL earnings summariesOMCL Stock 12 Month Forecast
Average Price Target
$1,063.70
▲(51.52% Upside)